Ten biopharmaceutical companies launched initial public offerings in the US during the last week of July, raising $1.2bn combined, bringing last month’s total to 18 IPOs. Added to the 62 first-time offerings during the first half of 2021, 80 drug developer have gone public so far this year, which means the industry is just six IPOs away from matching the record-breaking 2020 total of 86 IPOs.
The week of 26 to 30 July was a marked improvement from the prior week when just two of five companies that were expected to go public between 19 and 23 July actually launched their IPOs. Last month, which started with no IPOs during the US Fourth of July holiday week, outpaced any other month in 2021, beating June with 16 first-time offerings and February with 17 IPOs
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?